Urological Cancer 2022
In the urological sphere, the number of tumor malignancies caused by cancer is continuously growing in Western countries. Although this is mainly due to the contemporary increase in the life expectancy of people in these geographic areas, many other factors are also contributing to this growth. Urol...
Saved in:
| Format: | Online |
|---|---|
| Language: | English |
| Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Subjects: | |
| Online Access: | ONIX_20230405_9783036569680_246 |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1869515431905067008 |
|---|---|
| collection | Directory of Open Access Books |
| description | In the urological sphere, the number of tumor malignancies caused by cancer is continuously growing in Western countries. Although this is mainly due to the contemporary increase in the life expectancy of people in these geographic areas, many other factors are also contributing to this growth. Urological cancer is a complex and varied disease which affects different organs and mainly affects the male population. In fact, in most statistics, kidney, prostate, and bladder cancer are regularly included in the top-ten list of the most frequent neoplasms in males. The female population, however, has also been increasingly affected by renal and bladder cancer in the last decade. From these facts, it is clear that urological cancer is a problem of major concern in developed societies. This Topic Issue of Cancers intends to shed some light on the complexity of this field and will consider all useful and appropriate contributions from scientists and clinicians in order to improve urological cancer knowledge for patients’ benefit. |
| format | Online |
| id | doab-20.500.12854ir-98967 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2023 |
| publishDateRange | 2023 |
| publishDateSort | 2023 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-989672024-03-31T13:10:37Z Urological Cancer 2022 López, José I. Manini, Claudia high-risk prostate cancer androgen receptor axis castration resistance neuroendocrine carcinoma PARP inhibition immunotherapy cancer genome precision targeting robot-assisted partial nephrectomy renal cell carcinoma indocyanine green nephron sparing prostate cancer survivors follow-up care primary health care general practice process evaluation Consolidated Framework for Implementation Research prostate-specific membrane antigen positron-emission tomography multiparametric magnetic-resonance imaging primary diagnosis prostate cancer systematic review diagnosis PSMA PSA tumor PET scan bladder cancer bisphenol A bisphenol S energy metabolism migration proliferation carbon-ion radiotherapy elderly patients radiotherapy particle beam therapy life expectancy systemic immune-inflammation index Charlson comorbidity index CAPRA-S early survival male incontinence robotic prostatectomy clear cell renal cell carcinoma ferroptosis prognostic model TCGA E-MTAB-1980 GLS2 pazopanib real-world data non-interventional study time on drug nivolumab everolimus trial-eligibility ureteral neoplasms urinary bladder neoplasms ureteroscopy CNTF CNTFRα LNCaP 22Rv1 castration resistant castration sensitive STAT3 ERK MMP biomarker Gleason grade transforming growth factor-β family activin INHBA INHBB INHBC prostate-specific antigen false-positive results real world-data n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology In the urological sphere, the number of tumor malignancies caused by cancer is continuously growing in Western countries. Although this is mainly due to the contemporary increase in the life expectancy of people in these geographic areas, many other factors are also contributing to this growth. Urological cancer is a complex and varied disease which affects different organs and mainly affects the male population. In fact, in most statistics, kidney, prostate, and bladder cancer are regularly included in the top-ten list of the most frequent neoplasms in males. The female population, however, has also been increasingly affected by renal and bladder cancer in the last decade. From these facts, it is clear that urological cancer is a problem of major concern in developed societies. This Topic Issue of Cancers intends to shed some light on the complexity of this field and will consider all useful and appropriate contributions from scientists and clinicians in order to improve urological cancer knowledge for patients’ benefit. 2023-04-05T13:01:26Z 2023-04-05T13:01:26Z 2023 book ONIX_20230405_9783036569680_246 9783036569680 9783036569697 https://directory.doabooks.org/handle/20.500.12854/98967 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/7024 https://mdpi.com/books/pdfview/book/7024 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-6969-7 10.3390/books978-3-0365-6969-7 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036569680 9783036569697 238 Basel open access |
| spellingShingle | high-risk prostate cancer androgen receptor axis castration resistance neuroendocrine carcinoma PARP inhibition immunotherapy cancer genome precision targeting robot-assisted partial nephrectomy renal cell carcinoma indocyanine green nephron sparing prostate cancer survivors follow-up care primary health care general practice process evaluation Consolidated Framework for Implementation Research prostate-specific membrane antigen positron-emission tomography multiparametric magnetic-resonance imaging primary diagnosis prostate cancer systematic review diagnosis PSMA PSA tumor PET scan bladder cancer bisphenol A bisphenol S energy metabolism migration proliferation carbon-ion radiotherapy elderly patients radiotherapy particle beam therapy life expectancy systemic immune-inflammation index Charlson comorbidity index CAPRA-S early survival male incontinence robotic prostatectomy clear cell renal cell carcinoma ferroptosis prognostic model TCGA E-MTAB-1980 GLS2 pazopanib real-world data non-interventional study time on drug nivolumab everolimus trial-eligibility ureteral neoplasms urinary bladder neoplasms ureteroscopy CNTF CNTFRα LNCaP 22Rv1 castration resistant castration sensitive STAT3 ERK MMP biomarker Gleason grade transforming growth factor-β family activin INHBA INHBB INHBC prostate-specific antigen false-positive results real world-data n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology Urological Cancer 2022 |
| title | Urological Cancer 2022 |
| title_full | Urological Cancer 2022 |
| title_fullStr | Urological Cancer 2022 |
| title_full_unstemmed | Urological Cancer 2022 |
| title_short | Urological Cancer 2022 |
| title_sort | urological cancer 2022 |
| topic | high-risk prostate cancer androgen receptor axis castration resistance neuroendocrine carcinoma PARP inhibition immunotherapy cancer genome precision targeting robot-assisted partial nephrectomy renal cell carcinoma indocyanine green nephron sparing prostate cancer survivors follow-up care primary health care general practice process evaluation Consolidated Framework for Implementation Research prostate-specific membrane antigen positron-emission tomography multiparametric magnetic-resonance imaging primary diagnosis prostate cancer systematic review diagnosis PSMA PSA tumor PET scan bladder cancer bisphenol A bisphenol S energy metabolism migration proliferation carbon-ion radiotherapy elderly patients radiotherapy particle beam therapy life expectancy systemic immune-inflammation index Charlson comorbidity index CAPRA-S early survival male incontinence robotic prostatectomy clear cell renal cell carcinoma ferroptosis prognostic model TCGA E-MTAB-1980 GLS2 pazopanib real-world data non-interventional study time on drug nivolumab everolimus trial-eligibility ureteral neoplasms urinary bladder neoplasms ureteroscopy CNTF CNTFRα LNCaP 22Rv1 castration resistant castration sensitive STAT3 ERK MMP biomarker Gleason grade transforming growth factor-β family activin INHBA INHBB INHBC prostate-specific antigen false-positive results real world-data n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology |
| topic_facet | high-risk prostate cancer androgen receptor axis castration resistance neuroendocrine carcinoma PARP inhibition immunotherapy cancer genome precision targeting robot-assisted partial nephrectomy renal cell carcinoma indocyanine green nephron sparing prostate cancer survivors follow-up care primary health care general practice process evaluation Consolidated Framework for Implementation Research prostate-specific membrane antigen positron-emission tomography multiparametric magnetic-resonance imaging primary diagnosis prostate cancer systematic review diagnosis PSMA PSA tumor PET scan bladder cancer bisphenol A bisphenol S energy metabolism migration proliferation carbon-ion radiotherapy elderly patients radiotherapy particle beam therapy life expectancy systemic immune-inflammation index Charlson comorbidity index CAPRA-S early survival male incontinence robotic prostatectomy clear cell renal cell carcinoma ferroptosis prognostic model TCGA E-MTAB-1980 GLS2 pazopanib real-world data non-interventional study time on drug nivolumab everolimus trial-eligibility ureteral neoplasms urinary bladder neoplasms ureteroscopy CNTF CNTFRα LNCaP 22Rv1 castration resistant castration sensitive STAT3 ERK MMP biomarker Gleason grade transforming growth factor-β family activin INHBA INHBB INHBC prostate-specific antigen false-positive results real world-data n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology |
| url | ONIX_20230405_9783036569680_246 |